本文選題：I~III期非小細(xì)胞肺癌　切入點：預(yù)后相關(guān)因素　出處：《吉林大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:回顧性分析312例I~III期NSCLC患者臨床特征,并初步討論影響I~III期NSCLS患者無進(jìn)展生存期的有關(guān)因素,以有助于實現(xiàn)非小細(xì)胞肺癌的三級預(yù)防,控制疾病進(jìn)展。對象和方法:通過吉林大學(xué)第一醫(yī)院病案檢索系統(tǒng)收集2012年1月1日至2015年1月1日在吉林大學(xué)白求恩第一醫(yī)院就診并明確診斷的312例I~III期非小細(xì)胞肺癌患者的臨床資料,記錄內(nèi)容包括:非小細(xì)胞肺癌患者性別、年齡、文化程度、吸煙指數(shù),居住地、體重指數(shù)、TNM分期、病理類型、首診主訴、既往呼吸系統(tǒng)病史、腫瘤標(biāo)志物癌胚抗原(carcino-embryonic antigen CEA)及細(xì)胞角蛋白19片段(Cytokerantin-19-fragment CYFRA21-1)、堿性磷酸酶(alkaline phosphatase ALP)、卡氏功能狀態(tài)(Karnofsky Performance Status KPS)評分及白蛋白水平等,采用SPSS18.0統(tǒng)計軟件分析影響NSCLS無進(jìn)展生存時間的相關(guān)因素。結(jié)果:1、I~III期NSCLS患者總的1、2年無進(jìn)展生存率分別為51.6%和39.1%。中位無進(jìn)展生存時間為14個月。2、單因素分析中年齡、文化程度、居住地、吸煙指數(shù)、BMI、TNM分期、病理類型、首診主訴、既往呼吸系統(tǒng)病史、腫瘤標(biāo)志物CEA及CYFRA21-1、堿性磷酸酶及KPS評分與I~III期NSCLS患者無進(jìn)展生存期有關(guān)。尚未發(fā)現(xiàn)性別、腫瘤家族史及白蛋白水平等與I~III期NSCLS患者無進(jìn)展生存期相關(guān)。3、多因素分析顯示居住地、BMI、TNM分期、病理類型、治療前KPS評分是影響I~III期NSCLS患者預(yù)后的獨立因素。結(jié)論:1、居住地、BMI、TNM分期、病理類型、治療前KPS評分是影響I~III期NSCLS患者無進(jìn)展生存期(progression-freesurvival PFS)長短的獨立預(yù)后因素。2、居住地為農(nóng)村,BMI指數(shù)≥18.5,TNM分期處于I~II期,病理類型為鱗癌以及KPS評分≥90分的I~III期NSCLS患者預(yù)后較好,無進(jìn)展生存期較長。3、年齡,文化程度,吸煙指數(shù),首診主訴,既往呼吸系統(tǒng)病史,腫瘤標(biāo)志物CEA及CYFRA21-1,堿性磷酸酶與NSCLC的PFS長短未見統(tǒng)計學(xué)關(guān)聯(lián)。
[Abstract]:Objective: to retrospectively analyze the clinical features of 312 patients with stage III NSCLC, and to discuss the factors affecting the progressive survival of patients with stage I stage III NSCLS, so as to help realize the tertiary prevention of non-small cell lung cancer (NSCLC). Progress of disease control. Objects and methods: 312 cases of stage III Icara were collected from January 1st 2012 to January 1st 2015 in Bai Qiuen first Hospital, Jilin University, through the Medical record Retrieval system of the first Hospital of Jilin University. Clinical data of patients with cell lung cancer, The records included: sex, age, education, smoking index, residence, body mass index (BMI), TNM staging, pathological type, primary complaint, previous respiratory history, Tumor marker carcino-embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), alkaline phosphatase (ALP), Karnofsky Performance Status (KPSs) and albumin level, and so on. Results the overall 1 and 2 year progression free survival rates were 51.6% and 39.1 in patients with stage III NSCLS of NSCLS by using SPSS18.0 software. The median survival time of progression free patients was 14 months. The median survival time was 14 months. The median age and education level in univariate analysis were 1 and 2 years, respectively. Residence, smoking index, BMI-TNM staging, pathological type, primary complaint, previous respiratory history, tumor markers CEA and CYFRA21-1, alkaline phosphatase and KPS score were associated with progressive survival in patients with stage III NSCLS. No sex was found. Familial history and albumin levels were associated with progressive survival in patients with stage III NSCLS. Multivariate analysis showed that the location of BMI-TNM staging, pathological type, and so on. Before treatment, KPS score was an independent factor for the prognosis of patients with NSCLS in stage III. Conclusion: 1. Before treatment, KPS score was an independent prognostic factor of progressive progressive survival (PFS) in patients with NSCLS in stage III. The patients living in rural areas with KPS index 鈮，

本文編號：1614985